BTCY: AI 评分 52/100 — AI 分析 (4月 2026)

Biotricity, Inc. is a medical technology company focused on providing remote biometric data monitoring solutions. Their primary focus is on diagnostic and post-diagnostic solutions for chronic illnesses.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

Biotricity, Inc. delivers remote biometric data monitoring solutions, primarily in the United States, focusing on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Its Bioflux mobile cardiac telemetry solution and ECG analysis software position it in the competitive medical device market, serving medical, healthcare, and consumer segments.

BTCY是做什么的？

Biotricity, Inc., established as a medical technology company, specializes in biometric data monitoring solutions within the United States. The company's core mission revolves around providing remote monitoring solutions tailored for medical, healthcare, and consumer markets, with a particular emphasis on diagnostic and post-diagnostic applications for lifestyle-related and chronic illnesses. Biotricity's flagship product is the Bioflux mobile cardiac telemetry solution, an integrated ECG device designed for continuous heart monitoring. Complementing this hardware is their proprietary ECG analysis software, which analyzes and synthesizes patient ECG monitoring data to provide actionable insights for healthcare professionals. The company's solutions aim to improve patient outcomes and reduce healthcare costs through proactive monitoring and early detection of potential health issues. Headquartered in Redwood City, California, Biotricity is strategically located in a hub of technological innovation, allowing it to attract talent and foster partnerships within the medical technology ecosystem. The company continues to evolve its product offerings to address the growing demand for remote patient monitoring solutions.

BTCY的投资论点是什么？

Biotricity operates in the expanding remote patient monitoring market, driven by an aging population and increasing prevalence of chronic diseases. The company's Bioflux solution and ECG analysis software offer a comprehensive approach to cardiac monitoring, potentially reducing hospital readmissions and improving patient care. With a market capitalization of $0.01 billion, Biotricity's growth hinges on expanding its market share and securing regulatory approvals for new products. A gross margin of 81.1% indicates strong pricing power, but profitability remains a challenge with a negative P/E ratio of -1.83 and a negative profit margin of -26.0%. Key value drivers include increasing adoption of remote monitoring technologies, strategic partnerships with healthcare providers, and successful commercialization of its product pipeline. Investors should monitor the company's ability to achieve profitability and manage its cash flow effectively.

BTCY在哪个行业运营？

Biotricity operates within the medical device industry, specifically in the remote patient monitoring (RPM) market. This market is experiencing rapid growth, driven by factors such as the aging population, increasing prevalence of chronic diseases, and advancements in wearable technology. The competitive landscape includes established medical device companies and emerging technology startups. Biotricity's focus on cardiac monitoring positions it within a niche segment of the RPM market. The industry is also subject to stringent regulatory requirements, including FDA approvals and data privacy regulations.

Medical Devices

Healthcare

BTCY有哪些增长机遇？

Expansion of Bioflux into New Markets: Biotricity has the opportunity to expand the market reach of its Bioflux mobile cardiac telemetry solution beyond the United States. The global remote patient monitoring market is projected to reach $175.2 billion by 2027, presenting a significant opportunity for Biotricity to increase its revenue streams. This expansion could involve strategic partnerships with international distributors and adaptation of the Bioflux solution to meet local regulatory requirements. Timeline: 2-3 years.
Development of New Remote Monitoring Solutions: Biotricity can leverage its expertise in biometric data monitoring to develop new remote monitoring solutions for other chronic conditions, such as diabetes and respiratory diseases. The market for remote monitoring of diabetes is expected to grow significantly in the coming years, driven by the increasing prevalence of the disease. By diversifying its product portfolio, Biotricity can reduce its reliance on cardiac monitoring and tap into new revenue streams. Timeline: 3-5 years.
Strategic Partnerships with Healthcare Providers: Biotricity can form strategic partnerships with healthcare providers, such as hospitals and clinics, to integrate its Bioflux solution into their existing workflows. These partnerships can provide Biotricity with access to a large patient base and increase the adoption of its products. The healthcare industry is increasingly embracing remote patient monitoring as a way to improve patient outcomes and reduce costs. Timeline: Ongoing.
Integration with Telehealth Platforms: Biotricity can integrate its Bioflux solution with telehealth platforms to provide patients with remote access to healthcare professionals. The telehealth market is experiencing rapid growth, driven by the increasing demand for convenient and accessible healthcare services. By integrating with telehealth platforms, Biotricity can expand its reach and provide patients with a more comprehensive healthcare experience. Timeline: 1-2 years.
Leveraging AI and Machine Learning: Biotricity can leverage artificial intelligence (AI) and machine learning (ML) to enhance its ECG analysis software and provide more accurate and personalized insights to healthcare professionals. AI and ML can be used to identify patterns in patient data and predict potential health issues before they occur. This can improve patient outcomes and reduce the burden on healthcare systems. Timeline: Ongoing.

Market Cap of $0.01 billion reflects its position as a micro-cap company.
Gross Margin of 81.1% indicates strong potential for profitability if sales volume increases.
Negative P/E ratio of -1.83 suggests the company is currently not profitable.
Profit Margin of -26.0% highlights the need for improved cost management and revenue growth.
Beta of 1.40 indicates higher volatility compared to the overall market.

BTCY提供哪些产品和服务？

Develop and market the Bioflux mobile cardiac telemetry solution.
Provide ECG analysis software for synthesizing patient ECG monitoring data.
Offer remote monitoring solutions for medical, healthcare, and consumer markets.
Focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.
Provide solutions for continuous heart monitoring.
Offer software components for analyzing ECG data.

BTCY如何赚钱？

Sales of Bioflux mobile cardiac telemetry devices.
Subscription fees for ECG analysis software.
Partnerships with healthcare providers for remote patient monitoring services.

Hospitals and clinics.
Healthcare providers.
Patients with chronic illnesses.
Consumers seeking remote health monitoring solutions.

Proprietary ECG analysis software.
Integrated Bioflux mobile cardiac telemetry solution.
Focus on remote monitoring solutions for chronic illnesses.
Established relationships with healthcare providers.

什么因素可能推动BTCY股价上涨？

Ongoing: Expansion of Bioflux sales into new geographic markets.
Ongoing: Development of new remote monitoring solutions for other chronic conditions.
Ongoing: Strategic partnerships with healthcare providers to integrate Bioflux into their workflows.
Upcoming: Potential FDA approval for new product features or enhancements.
Ongoing: Integration of Bioflux with telehealth platforms to expand reach.

BTCY的主要风险是什么？

Potential: Competition from larger, more established medical device companies.
Potential: Regulatory hurdles and delays in FDA approval processes.
Potential: Reimbursement challenges from insurance providers for remote monitoring services.
Ongoing: Dependence on a single product line (Bioflux).
Ongoing: Limited financial resources to support growth initiatives.

BTCY的核心优势是什么？

Proprietary Bioflux mobile cardiac telemetry solution.
ECG analysis software provides actionable insights.
Focus on remote monitoring aligns with market trends.
High gross margin of 81.1%.

BTCY的劣势是什么？

Negative P/E ratio indicates lack of profitability.
Limited market share compared to larger competitors.
Reliance on a single product line (Bioflux).
OTC market listing may limit investor access.

BTCY有哪些机遇？

Expansion into new geographic markets.
Development of new remote monitoring solutions for other chronic conditions.
Strategic partnerships with healthcare providers.
Integration with telehealth platforms.

BTCY面临哪些威胁？

Competition from established medical device companies.
Regulatory hurdles and FDA approval processes.
Reimbursement challenges from insurance providers.
Technological advancements by competitors.

BTCY的竞争对手是谁？

iRhythm Technologies, Inc. — Offers wearable biosensors for cardiac monitoring. — (ALRTF)
Asante Solutions, Inc. — Focuses on diabetes management solutions. — (ASAPF)
CalciMedica, Inc. — Develops therapies for inflammatory and autoimmune diseases. — (CLCS)
Corvus Pharmaceuticals, Inc. — Develops cancer immunotherapies. — (CRVW)
Global Blood Therapeutics, Inc. — Focuses on therapies for blood disorders. — (GLABF)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Waqaas Al-Siddiq
Headquarters: Redwood City, US
Employees: 55
Founded: 2018

AI Insight

AI analysis pending for BTCY

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Biotricity, Inc. do?

Biotricity, Inc. is a medical technology company that specializes in providing remote biometric data monitoring solutions. Its primary product, the Bioflux mobile cardiac telemetry solution, is an integrated ECG device used for continuous heart monitoring. The company also offers ECG analysis software that analyzes and synthesizes patient ECG monitoring data. Biotricity focuses on delivering diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses, serving medical, healthcare, and consumer markets in the United States. The company's goal is to improve patient outcomes and reduce healthcare costs through proactive monitoring and early detection.

What do analysts say about BTCY stock?

As of 2026-03-16, a comprehensive analyst consensus for BTCY is not available due to its OTC listing and limited coverage. Key valuation metrics such as price targets and earnings estimates may not be readily accessible. the may be worth researching company's growth potential in the remote patient monitoring market, its financial performance (including gross margin and profitability), and the risks associated with its OTC listing. Further independent research and due diligence are recommended before making any investment decisions.

What are the main risks for BTCY?

Biotricity faces several risks, including competition from larger medical device companies, regulatory hurdles and FDA approval processes, and reimbursement challenges from insurance providers for remote monitoring services. The company's dependence on a single product line (Bioflux) and its limited financial resources also pose significant risks. Additionally, its OTC listing exposes investors to higher price volatility and limited liquidity. Successful mitigation of these risks is crucial for Biotricity's long-term growth and sustainability.